DESONIDE SODIUM PHOSPHATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C24H31O9P.2Na
Molecular Weight	540.4508
Optical Activity	UNSPECIFIED
Defined Stereocenters	8 / 8
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].[Na+].CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)COP([O-])([O-])=O

InChI

InChIKey=IHTZFPUWMRSEMG-PXQDNWDYSA-L

InChI=1S/C24H33O9P.2Na/c1-21(2)32-19-10-16-15-6-5-13-9-14(25)7-8-22(13,3)20(15)17(26)11-23(16,4)24(19,33-21)18(27)12-31-34(28,29)30;;/h7-9,15-17,19-20,26H,5-6,10-12H2,1-4H3,(H2,28,29,30);;/q;2*+1/p-2/t15-,16-,17-,19+,20+,22-,23-,24+;;/m0../s1

HIDE SMILES / InChI

Molecular Formula	C24H31O9P
Molecular Weight	494.4713
Charge	-2
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	8 / 8
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	Na
Molecular Weight	22.98976928
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8db13f47-aaab-4054-8b0d-0e23d44dc848

Desonide is a topical glucocorticoid which was approved by FDA for the treatment of such conditions as eczema, psoriasis, atopic dermatitis, etc. The exact mechanism of drug action is unknown.

Approval Year

Conditions

Condition	Modality	Highest Phase	Product
Atopic dermatitis 64 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8db13f47-aaab-4054-8b0d-0e23d44dc848	Primary	Approved 8583	DESONIDE Approved Use Desonide Ointment, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. It should not be used for longer than two weeks unless directed by a physician. Launch Date 1972
Eczema 46 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8db13f47-aaab-4054-8b0d-0e23d44dc848	Primary	Approved 8583	DESONIDE Approved Use Desonide Cream, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. Launch Date 1972
Seborrheic dermatitis 15 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8db13f47-aaab-4054-8b0d-0e23d44dc848	Primary	Approved 8583	DESONIDE Approved Use Desonide Cream, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. Launch Date 1972
Contact dermatitis 20 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8db13f47-aaab-4054-8b0d-0e23d44dc848	Primary	Approved 8583	DESONIDE Approved Use Desonide Cream, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. Launch Date 1972
Psoriasis 87 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8db13f47-aaab-4054-8b0d-0e23d44dc848	Primary	Approved 8583	DESONIDE Approved Use Desonide Cream, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. Launch Date 1972

Doses

Dose	Population	Adverse events
0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf	Disc. AE: Cushing's syndrome, Hypothalamic pituitary adrenal axis suppression... AEs leading to discontinuation/dose reduction: Cushing's syndrome Hypothalamic pituitary adrenal axis suppression Atrophy Striae Irritation skin Acneiform eruption Skin hypopigmentation Allergic contact dermatitis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf
0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf	Disc. AE: Telangiectasia... AEs leading to discontinuation/dose reduction: Telangiectasia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf

AEs

AE	Significance	Dose	Population
Acneiform eruption	Disc. AE	0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf
Allergic contact dermatitis	Disc. AE	0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf
Atrophy	Disc. AE	0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf
Cushing's syndrome	Disc. AE	0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf
Hypothalamic pituitary adrenal axis suppression	Disc. AE	0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf
Irritation skin	Disc. AE	0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf
Skin hypopigmentation	Disc. AE	0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf
Striae	Disc. AE	0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf
Telangiectasia	Disc. AE	0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21324lbl.pdf#page=4 Page: 4,8	yes		yes (co-administration study) Comment: Concomitant oral administration of ketoconazole (a known inhibitor of CYP3A4 activity in the liver and in the intestinal mucosa) caused an eight-fold increase of the systemic exposure to oral budesonide. If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21324lbl.pdf#page=4 Page: 4,8

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:204734	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:204734
ChemicalBook	CB2783466	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2783466
eMolecules	31225502	https://www.emolecules.com/cgi-bin/more?vid=31225502
eMolecules	6842825	https://www.emolecules.com/cgi-bin/more?vid=6842825
MolPort	MolPort-003-987-087	https://www.molport.com/shop/molecule-link/MolPort-003-987-087
Selleck Chemicals	Desonide	http://www.selleckchem.com/products/Desonide.html
ZINC	ZINC000004212851	http://zinc15.docking.org/substances/ZINC000004212851

PubMed

Title	Date	PubMed
Pediatric atopic dermatitis: a review of the medical management.	2010-09	20628042
Update on the management of chronic eczema: new approaches and emerging treatment options.	2010-07-28	21437065
Good adherence and early efficacy using desonide hydrogel for atopic dermatitis: results from a program addressing patient compliance.	2010-04	20514788
Generic sample preparation combined with high-resolution liquid chromatography-time-of-flight mass spectrometry for unification of urine screening in doping-control laboratories.	2010-04	20155493
Vitiligo after diphencyprone for alopecia areata.	2010	20585597
Lenalidomide-induced acute acneiform folliculitis of the head and neck: not only the anti-EGF receptor agents.	2010	19907136
Rhabdomyomatous mesenchymal hamartoma: clinical overview and report of a case with spontaneous regression.	2009-12	20583694
An investigator-blind, randomized, 4-week, parallel-group, multicenter pilot study to compare the safety and efficacy of a nonsteroidal cream (Promiseb Topical Cream) and desonide cream 0.05% in the twice-daily treatment of mild to moderate seborrheic dermatitis of the face.	2009-11-03	19878781
Drugs associated with more suicidal ideations are also associated with more suicide attempts.	2009-10-02	19798416
Inflammation of actinic keratosis with combination of alkylating and taxane agents: a case report.	2009-07-02	19829884
Manifestations of cutaneous sarcoidosis: a case report of an African American woman.	2009-06	19585935
Fixed drug eruption induced by atenolol.	2009-04-24	21437137
A simple and rapid ESI-LC-MS/MS method for simultaneous screening of doping agents in urine samples.	2009-04	20336223
Treatment of scalp and facial seborrheic dermatitis with desonide hydrogel 0.05%.	2009-02	20967179
[Streptococcal perianal dermatitis and guttate psoriasis].	2009-01	19171228
What's your assessment? Severe seborrheic dermatitis.	2008-12	19241741
Direct injection LC/ESI-MS horse urine analysis for the quantification and identification of threshold substances for doping control. I. Determination of hydrocortisone.	2008-09	18407581
Desonide foam 0.05%: safety in children as young as 3 months.	2008-08	18638631
Nephrotic state as a risk factor for developing posterior reversible encephalopathy syndrome in paediatric patients with nephrotic syndrome.	2008-08	18258739
Desonide: a review of formulations, efficacy and safety.	2008-07	18549345
Worrisome perioral rash on a young boy. Lip-licker's dermatitis.	2008-05	18556883
New and emerging trends in the treatment of atopic dermatitis.	2008-02-02	19920986
Adverse cutaneous drug reaction.	2008-01	19967009
Desonide foam: a review.	2008-01	18301804
Corticosteroid therapy in the treatment of pediatric patients with atopic dermatitis.	2007-09-20	21289943
Desonide gel.	2007-09-06	17786103
Tega-dermabrasion.	2007-09	17721261
Efficacy of desonide 0.05% cream and lotion in steroid-responsive dermatoses in Indian patients: a post-marketing surveillance study.	2007-07-24	17642640
A novel hydrogel vehicle formulated for the treatment of atopic dermatitis.	2007-07	17763596
Effect of desonide hydrogel 0.05% on the hypothalamic-pituitary-adrenal axis in pediatric subjects with moderate to severe atopic dermatitis.	2007-06-05	17542883
Ketoconazole gel 2% in the treatment of moderate to severe seborrheic dermatitis.	2007-06	17713152
Periorbital cutaneous neonatal lupus.	2007-05-08	17483660
Safety and efficacy of desonide hydrogel 0.05% in pediatric subjects with atopic dermatitis.	2007-02	17373176
Verdeso (desonide) Foam, 0.05%.	2007-01-12	17215617
Photochemistry of desonide, a non-fluorinated steroidal anti-inflammatory drug.	2006-06	16755054
Erythematous scaling eyelids: patient history, exposure to allergens and irritants are keys to diagnosis.	2005-06	16001768
Rapid resolution of a common problem.	2005-05	15866247
[Connubial contact dermatitis to an inhaled corticosteroid].	2005-02	15798566
Seborrheic dermatitis.	2005-01-18	15654167
Comparison of the analysis of corticosteroids using different techniques.	2005-01	15700162
Two case reports of cutaneous adverse reactions following hepatitis B vaccine: lichen planus and granuloma annulare.	2004-09	15324406
Overview on desonide 0.05%: a clinical safety profile.	2004-08-12	15303783
Corneofungimetry bioassay on Malassezia spp. under ketoconazole and desonide influences.	2004-03-08	15767771
Steroid therapy altered serum levels of CCL2 and CCL5 chemokines in multiple sclerosis patients during relapse.	2004	15550762
Evaluation of cross-reactivity between budesonide and desonide.	2002-08	12423417
Efficacy, cutaneous tolerance and cosmetic acceptability of desonide 0.05% lotion (Desowen) versus vehicle in the short-term treatment of facial atopic or seborrhoeic dermatitis.	2002-08	12121395
Efficacy and safety of desonide phosphate for the treatment of allergic conjunctivitis.	2002-07	12072722
A double-blind placebo-controlled study of ketoconazole + desonide gel combination in the treatment of facial seborrheic dermatitis.	2002	12077544
Allergic contact dermatitis from topical corticosteroids.	1989-08	2530056
Clinical comparison of alclometasone dipropionate and desonide ointments (0.05%) in the management of psoriasis.	1982	6754511

Patents

Sample Use Guides

In Vivo Use Guide

Desonide Cream, 0.05% should be applied to the affected area as a thin film two to four times daily depending on the severity of the condition.

Route of Administration: Topical

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 22:27:45 GMT 2025` Edited by `admin` on `Mon Mar 31 22:27:45 GMT 2025`
Record UNII	36H4OGY275
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DESONIDE SODIUM PHOSPHATE

Common Name

English

PRENACID

Preferred Name

English

PREGNA-1,4-DIENE-3,20-DIONE, 11-HYDROXY-16,17-((1-METHYLETHYLIDENE)BIS(OXY))-21-(PHOSPHONOOXY)-, DISODIUM SALT, (11.BETA.,16.ALPHA.)-

Systematic Name

English

PHOSPHORIC ACID 11.BETA.,21-DIHYDROXY-16.ALPHA.,17-((1-METHYLETHYLIDENE)BIS(OXY))-3,20-DIOXOPREGNA-1,4-DIENE-21-YL, DISODIUM SALT

Systematic Name

English

J404.068F

Code

English

DESONIDE 21-PHOSPHATE DISODIUM SALT

Common Name

English

DESONIDE DISODIUM PHOSPHATE

Common Name

English

Desonide Disodium Phosphate [WHO-DD]

Common Name

English

Code System Code Type Description

CAS

94087-98-6